	US 11,717,565 B2
	Recombinant BCG overexpressing phoP-phoR
Jun Liu, Oakville (CA)
Assigned to CHENGDU ANYONG DINGYE BIOTECHNOLOGY CO., LTD., Chengdu (CN); and LTD., Chengdu (CN)
Appl. No. 16/500,934
Filed by Chengdu Anyong Dingye Biotechnology Co., Ltd., Chengdu (CN)
PCT Filed Apr. 7, 2017, PCT No. PCT/CN2017/079665 § 371(c)(1), (2) Date Oct. 4, 2019, PCT Pub. No. WO2018/184188, PCT Pub. Date Oct. 11, 2018.
Prior Publication US 2020/0254080 A1, Aug. 13, 2020
Int. Cl. A61K 39/04 (2006.01); A61P 31/06 (2006.01); C12N 1/20 (2006.01); C12R 1/32 (2006.01)

CPC A61K 39/04 (2013.01) [A61P 31/06 (2018.01); C12N 1/20 (2013.01); C12N 1/205 (2021.05); C12R 2001/32 (2021.05)]

9 Claims

1. A live recombinant Mycobacterium bovis-BCG strain comprising nucleic acids capable of overexpression and overexpressing both PhoP and PhoR proteins, the recombinant Mycobacterium bovis-BCG strain having improved immunogenicity compared to wild type nonrecombinant Mycobacterium bovis-BCG strain, the recombinant Mycobacterium bovis-BCG strain having virulence comparable with wild type nonrecombinant Mycobacterium bovis-BCG strain, and the recombinant Mycobacterium bovis-BCG strain having a decreased virulence compared to recombinant Mycobacterium bovis-BCG strain overexpressing only PhoP.